NeuRizer Ltd (NRZ) AI Stock Analysis

• Market Cap: AU$3.36M
• Dividend Yield: N/A
• Average Volume (3M): 10.00M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.16
• Revenue Growth: N/A
• EPS Growth: 74.00%
• Country: AU
• Employees: N/A
• Sector: Basic Materials
• Sector Strength: 68
• Industry: Oil & Gas Midstream
• EPS (TTM): >-0.01
• Shares Outstanding: 3,358,004,000
• 10 Day Avg. Volume: 9,997,589
• 30 Day Avg. Volume: 9,997,589
• PEG Ratio: 0.10
• Price to Book (P/B): 0.84
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.77
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 38 Underperform
• Price Target: ―

The overall stock score for NeuRizer Ltd is primarily impacted by its poor financial performance, characterized by persistent losses and negative cash flows. The lack of technical analysis data and unfavorable valuation metrics further contribute to a low score. Despite a stable balance sheet with low leverage, the company's inability to achieve profitability and generate positive cash flows poses significant risks to its financial health and attractiveness to investors.

NeuRizer Ltd Business Overview & Revenue Model

Company Description

NeuRizer Ltd. focuses on producing carbon neutral fertilisers in Australia. It has NeuRizer Urea project that deliver nitrogen-based fertilizers for agricultural markets in south Australia. NeuRizer Ltd. was formerly known as Leigh Creek Energy Limited and changed its name to NeuRizer Ltd. in March 2022. The company was incorporated in 2004 and is based in Adelaide, Australia.

How the Company Makes Money

NeuRizer Ltd generates revenue primarily through the sale of urea, a key agricultural fertilizer, produced at its NeuRizer Urea Project. The company capitalizes on its strategic location, advanced technology, and integration capabilities to ensure cost-effective production and distribution. NeuRizer also engages in strategic partnerships and joint ventures to enhance its operational efficiency and market reach. Additionally, the company may explore opportunities in related sectors, such as carbon capture and storage, to diversify its income streams.

NeuRizer Ltd Financial Statement Overview

Summary

NeuRizer Ltd faces significant financial challenges, with persistent losses and cash flow issues. The lack of revenue generation and continued operational inefficiencies highlight ongoing struggles in achieving profitability. Although the balance sheet shows limited leverage, the company's inability to produce positive cash flows and net income poses substantial risks to financial stability.

Income Statement

NeuRizer Ltd has consistently reported zero revenue over the years, leading to negative gross profit and significant negative net income. The company's EBIT and EBITDA margins are also negative, indicating operational inefficiencies and a lack of profitability. The absence of revenue growth further compounds these issues, reflecting ongoing challenges in generating sales and controlling costs.

Balance Sheet

The balance sheet shows a reasonable equity ratio, suggesting that the company is not overly reliant on debt financing. However, the consistent negative net income detracts from potential returns on equity. The debt-to-equity ratio remains low, indicating limited financial leverage, which could be beneficial for stability but also highlights the company's difficulty in generating returns.

Cash Flow

NeuRizer Ltd's cash flow situation is concerning, with negative free cash flow persisting over the years, reflecting ongoing cash outflows exceeding inflows. The operating cash flow to net income ratio is negative, which suggests poor operational cash generation relative to net losses. Despite occasional financing inflows, the company's cash management remains a critical challenge.

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
-31.45K	-45.39K	-159.00K	-180.00K	-77.68K
	EBIT
-2.80M	-12.60M	-12.45M	-8.86M	-7.03M
	EBITDA
-4.48M	-12.55M	-12.29M	-8.68M	-6.92M
	Net Income Common Stockholders
-5.60M	-16.26M	-20.40M	-13.57M	-7.16M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
568.72K	1.21M	1.07M	22.81M	6.81M
	Total Assets
129.32M	128.67M	91.61M	55.18M	35.93M
	Total Debt
2.11M	2.44M	321.77K	224.84K	822.07K
	Net Debt
1.54M	1.23M	-121.48K	-22.59M	-5.99M
	Total Liabilities
56.30M	55.91M	35.12M	3.88M	1.78M
	Stockholders Equity
73.02M	72.75M	56.49M	51.30M	34.16M
Cash Flow		Free Cash Flow
-6.09M	-34.32M	-16.47M	-8.27M	-1.86M
	Operating Cash Flow
-3.56M	-9.05M	-10.23M	-4.61M	904.92K
	Investing Cash Flow
826.61K	-16.11M	-27.63M	-3.14M	-2.76M
	Financing Cash Flow
2.09M	25.92M	15.49M	23.75M	6.38M

NeuRizer Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IPC	72 Outperform	AU$9.04M	17.97	5.45%	4.12%	74.85%	170.29%
Sector *	51 Neutral	$2.03B	-1.27	-21.09%	4.14%	2.90%	-30.49%
MRD	41 Neutral	AU$1.56M	―	-94.58%	―	―	15.56%
EMT	40 Underperform	AU$2.55M	―	-41.47%	―	―	-528.57%
NRZ	38 Underperform	AU$3.36M	―	-7.69%	―	―	74.00%
AOA	31 Underperform	AU$2.85M	―	-66.25%	―	―	-80.00%
SHP	29 Underperform	AU$3.31M	―	-296.02%	―	―	63.35%

NeuRizer Ltd Corporate Events

NeuRizer Ltd Faces ASX Suspension Over Reporting Delay

NeuRizer Ltd, along with several other companies, has been suspended from quotation on the ASX due to not lodging the required periodic report by the due date. This suspension may impact the company’s market operations and investor confidence until the report is submitted and the suspension is lifted.

NeuRizer Ltd Announces New Securities Quotation on ASX

NeuRizer Ltd has announced the quotation of 133,333,333 ordinary fully paid securities on the ASX, marking a significant step in their financial strategy. This move could enhance the company’s market presence and provide additional capital for growth, potentially benefiting stakeholders and strengthening its competitive positioning.

NeuRizer Announces Planned Issuance of 133 Million Securities

NeuRizer Ltd has announced a proposed issuance of 133,333,333 ordinary fully paid securities. The issuance is scheduled for February 20, 2025, with the intention of having these securities quoted on the ASX, subject to approval. This move could potentially enhance NeuRizer’s capital base, providing increased operational flexibility and possibly influencing its market standing.

NeuRizer Ltd Completes $200K Private Share Placement

NeuRizer Ltd has successfully completed a private share placement to raise $200,000 through the issuance of 133,333,333 new fully paid ordinary shares at $0.0015 per share. The funds raised will be used for general working capital, specifically to aid progress on the NeuRizer Urea Project, indicating an ongoing commitment to advancing its projects and potentially strengthening its market position.

NeuRizer Ltd Issues 78 Million Unquoted Equity Securities

NeuRizer Ltd has announced the issuance of 78,000,000 unquoted equity securities, specifically options expiring on May 29, 2028. This move is part of its employee incentive scheme, which reflects the company’s ongoing efforts to incentivize its workforce and align their goals with the company’s long-term strategies, potentially strengthening its market position.

NeuRizer Ltd Announces Quotation of 159.8 Million New Securities

NeuRizer Ltd, a company listed on the ASX under the code NRZ, has announced the quotation of 159,800,000 ordinary fully paid securities as of February 7, 2025, as part of previously announced transactions. This move potentially impacts the company’s market presence and operational liquidity, providing an opportunity for stakeholders to assess its financial strategy in light of these additional securities.